757 top medical experts on Thrombotic Thrombocytopenic Purpura across 37 countries and 37 U.S. states, including 671 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Thrombotic Thrombocytopenic Purpura: An acquired, congenital, or familial disorder caused by platelet aggregation with thrombosis in terminal arterioles and capillaries. Clinical features include thrombocytopenia; hemolytic anemia; azotemia; fever; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as renal failure. Mutations in the adamts13 protein gene have been identified in familial cases.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Thrombocytopenic Purpura (453), Thrombophilia (2,217).
  4. Clinical Trials ClinicalTrials.gov : at least 46 including 1 Active, 15 Completed, 10 Recruiting
  5. Synonyms: Moschkowitz Disease,  Thrombotic Thrombopenic Purpura,  Congenital Thrombotic Thrombocytopenic Purpura,  Familial Thrombotic Thrombocytopenic Purpura


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Cataland, Spero R   Hematology   ClinicalTrials.gov Google Publications
    Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medical school: Ohio State University College of Medicine (MD, 1994)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 82.3/100
    Disclosed payments in 2021 from 12 biomedical companies, totalling $34,325.46, including $19,900 from  Takeda Pharmaceuticals U.S.A., Inc.
    Subjects: Purpura, Thrombotic Thrombocytopenic; ADAM Proteins; Single-Domain Antibodies; Von Willebrand Factor; Complement Activation; Fibrinolytic Agents
    Categories: Diagnosis; Therapeutic Use; Blood; Drug Therapy; Etiology; Therapy
    Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. (2019)
    Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. (2016)

  2. Scully, Marie A   ClinicalTrials.gov Google Publications
    Department of Haematology, University College London Hospital, London, United Kingdom.
    Scientist  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports 
    Subjects: Purpura, Thrombotic Thrombocytopenic; ADAM Proteins; ADAMTS13 Protein; Antibodies, Monoclonal, Murine-Derived; Single-Domain Antibodies; Autoantibodies
    Categories: Therapeutic Use; Immunology; Therapy; Drug Therapy; Diagnosis; Blood
    Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. (2019)
    Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. (2012)

  3. George, James N   Hematology & Oncology   Google Publications
    Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports  Review 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 52/100
    Subjects: Purpura, Thrombotic Thrombocytopenic; ADAM Proteins; Hemolytic-Uremic Syndrome; Registries; ADAMTS13 Protein; Plasma Exchange
    Categories: Diagnosis; Therapy; Therapeutic Use; Blood; Epidemiology; Etiology
    Redefining outcomes in immune TTP: an international working group consensus report. (2021)
    Survival and relapse in patients with thrombotic thrombocytopenic purpura. (2010)

  4. Coppo, Paul   ClinicalTrials.gov Google Publications
    Centre de Référence des Microangiopathies Thrombotiques, Service dHématologie, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris and Sorbonne Université, Paris, France.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Purpura, Thrombotic Thrombocytopenic; ADAMTS13 Protein; Plasma Exchange; ADAM Proteins; Purpura, Thrombocytopenic, Idiopathic; Rituximab
    Categories: Genetics; Therapeutic Use; Therapy; Diagnosis; Immunology; Blood
    Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. (2019)
    Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. (2017)

  5. Kremer, Hovinga Johanna A   Google Publications
    Department of Hematology, Bern University Hospital, University of Bern, Bern, Switzerland.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Purpura, Thrombotic Thrombocytopenic; ADAM Proteins; ADAMTS13 Protein; Autoantibodies; Von Willebrand Factor; Hemolytic-Uremic Syndrome
    Categories: Genetics; Immunology; Blood; Diagnosis; Therapeutic Use; Drug Therapy
    Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. (2019)
    Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. (2016)

  6. Peyvandi, Flora     Google Publications
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports 
    Subjects: Purpura, Thrombotic Thrombocytopenic; ADAM Proteins; Von Willebrand Factor; ADAMTS13 Protein; Mutation; Autoantibodies
    Categories: Genetics; Blood; Immunology; Diagnosis; Therapeutic Use; Drug Therapy
    Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. (2019)
    Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. (2012)

  7. Friedman, Kenneth D   Hematology & Oncology  Google Publications
    Division of Benign Hematology, Medical College of Wisconsin, Milwaukee, WI.
    Physician  Highly Cited  Highly Published  Case Reports 
    Disclosed payments in 2021 from 5 biomedical companies, totalling $6,055.78, including $4,205.78 from  GENZYME CORPORATION
    Subjects: Purpura, Thrombotic Thrombocytopenic; Anemia, Pernicious; Vitamin B 12; ADAM Proteins; ADAMTS13 Protein; Anaphylaxis
    Categories: Diagnosis; Administration & Dosage; Genetics; Pathology; Prevention & Control; Therapy
    Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. (2017)
    Redefining outcomes in immune TTP: an international working group consensus report. (2021)

  8. Chaturvedi, Shruti   Medical Oncology  Google Publications
    Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. Top Hospital
    Physician  Highly Cited  Highly Published 
    Relevant US NIH Grant Funding: $693,900 over the last 5 years
    Disclosed payments in 2021 from 9 biomedical companies, totalling $26,680, including $10,800 from  GENZYME CORPORATION
    Subjects: Purpura, Thrombotic Thrombocytopenic; ADAMTS13 Protein; Purpura, Thrombocytopenic, Idiopathic; Single-Domain Antibodies; Stroke; Bortezomib
    Categories: Therapeutic Use; Etiology; Complications; Diagnosis; Blood; Drug Therapy
    Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. (2019)
    How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns. (2019)

  9. Bendapudi, Pavan K   Hematology & Oncology   Google Publications
    Division of Hematology and Blood Transfusion Service, Massachusetts General Hospital, Boston, MA, USA; Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA. Electronic address: . Top Hospital
    Physician  Highly Published  Case Reports 
    Disclosed payments in 2021 from 2 biomedical companies, totalling $3,310, including $2,760 from  Takeda Pharmaceuticals U.S.A., Inc.
    Subjects: Purpura, Thrombotic Thrombocytopenic; Single-Domain Antibodies; Thrombotic Microangiopathies; Abruptio Placentae; Costs and Cost Analysis; Disease Management
    Categories: Complications; Economics; Adverse Effects; Diagnosis; Drug Therapy; Etiology
    Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. (2021)
    Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura. (2020)

  10. Makar, Robert S   Anatomic Pathology & Clinical Pathology   Google Publications
    Blood Transfusion Service, Massachusetts General Hospital, Boston, MA, USA. Top Hospital
    Physician  Case Reports 
    Medical school: University of Texas Southwestern Medical School at Dallas (MD, 2000)
    Medicare Accepted
    Subjects: Purpura, Thrombotic Thrombocytopenic; Costs and Cost Analysis; Disease Management; Kidney; Lupus Nephritis; Plasma Exchange
    Categories: Complications; Adverse Effects; Diagnosis; Etiology; Methods; Mortality
    Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura. (2020)
    Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative. (2019)

  11. Brodsky, Robert A   Hematology  Google Publications
    Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. Top Hospital
    Physician 
    Relevant US NIH Grant Funding: $1,620,000 over the last 5 years
    Medical school: Hahnemann University College of Medicine (MD, 1989)
    Medicare Accepted
    Disclosed payments in 2021 from 5 biomedical companies, totalling $6,256.13, including $6,256.13 from  Alexion Pharmaceuticals, Inc.
    Subjects: Purpura, Thrombotic Thrombocytopenic; ADAMTS13 Protein; Cardiovascular Diseases; Purpura, Thrombocytopenic, Idiopathic; Research Design; Stroke
    Categories: Complications; Diagnosis; Etiology; Metabolism; Statistics & Numerical Data
    Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. (2019)
    Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals. (2021)

  12. Streiff, Michael B   Hematology & Oncology  Google Publications
    Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD. Top Hospital
    Physician  Case Reports 
    Medical school: Johns Hopkins University School of Medicine (MD, 1988)
    Medicare Accepted
    Disclosed payments from biomedical company (PFIZER INC.) in 2021 for $4,500
    Subjects: Purpura, Thrombotic Thrombocytopenic; ADAMTS13 Protein; Stroke; Takotsubo Cardiomyopathy
    Categories: Complications; Etiology; Epidemiology; Metabolism; Therapy
    Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. (2019)
    Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: clinical outcomes and risk factors for relapse. (2010)

  13. Uhl, Lynne   Anatomic Pathology & Clinical Pathology  Google Publications
    Harvard Medical School, Boston, Massachusetts. Top Hospital
    Physician 
    Medical school: University of Cincinnati College of Medicine (MD, 1988)
    Medicare Accepted
    Disclosed payments in 2021 from 4 biomedical companies, totalling $4,575, including $3,575 from  Grifols Diagnostic Solutions, Inc.
    Subjects: Purpura, Thrombotic Thrombocytopenic; Plasma Exchange; Hemolytic-Uremic Syndrome; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Costs and Cost Analysis
    Categories: Mortality; Therapy; Administration & Dosage; Adverse Effects; Drug Therapy; Complications
    Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura. (2020)
    Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative. (2019)

  14. Rodgers, George M   Hematology  Google Publications
    Division of Hematology and Hematologic Malignancies, University of Utah Health Sciences Center, Salt Lake City, UT, 84112, USA. Top Hospital
    Physician  Highly Published  Case Reports 
    Medical school: Tulane University School of Medicine (MD, 1976)
    Medicare Accepted
    Disclosed payments in 2021 from 9 biomedical companies, totalling $16,823.32, including $9,080 from  Dova Pharmaceuticals
    Subjects: Purpura, Thrombotic Thrombocytopenic; ADAM Proteins; Plasma Exchange; Acute Kidney Injury; Plasma; Pregnancy Complications
    Categories: Therapy; Diagnosis; Blood; Deficiency; Enzymology; Epidemiology
    The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange. (2010)
    Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort. (2013)

  15. Ewenstein, Bruce M   Internal Medicine  Google Publications
    Baxalta US Inc., A Member of the Takeda Group of Companies, Cambridge, MA, USA.
    Physician  Clinical Trial 
    Subjects: Purpura, Thrombotic Thrombocytopenic; ADAMTS13 Protein; Cost of Illness; Health Expenditures; Health Resources
    Categories: Administration & Dosage; Blood; Drug Therapy; Economics; Genetics; Pharmacokinetics
    Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. (2017)
    Health care utilization of patients diagnosed with idiopathic thrombotic thrombocytopenic purpura in a commercially insured population in the United States. (2012)

  16. Maitta, Robert W   Chemical Pathology   Google Publications
    University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America. Electronic address: . Top Hospital
    Physician  Highly Published  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 88/100
    Disclosed payments from biomedical company (SANOFI-AVENTIS U.S. LLC) in 2021 for $30.33
    Subjects: Purpura, Thrombotic Thrombocytopenic; Platelet Count; ADAMTS13 Protein; Blood Platelets; Hemolytic-Uremic Syndrome; Immunosuppression Therapy
    Categories: Blood; Mortality; Antagonists & Inhibitors; Diagnosis; Genetics; Metabolism
    Absolute immature platelet count dynamics in diagnosing and monitoring the clinical course of thrombotic thrombocytopenic purpura. (2015)
    Absolute immature platelet count dynamics of thrombotic thrombocytopenic purpura patients with high ADAMTS13 inhibitor. (2019)

  17. Veyradier, Agnès   Google Publications
    Service dHématologie Biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris and EA3518, Institut de recherche Saint Louis, Université de Paris, Paris, France; and.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Purpura, Thrombotic Thrombocytopenic; ADAMTS13 Protein; Purpura, Thrombocytopenic, Idiopathic; Rituximab; Immunologic Factors; Plasma Exchange
    Categories: Genetics; Therapeutic Use; Immunology; Therapy; Diagnosis; Etiology
    A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. (2021)
    Redefining outcomes in immune TTP: an international working group consensus report. (2021)

  18. Zimrin, Ann B   Hematology & Oncology  Google Publications
    Division of Hematology-Oncology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, Maryland.
    Physician  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 93/100
    Subjects: Purpura, Thrombotic Thrombocytopenic; Antibodies, Monoclonal; HIV Infections; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents
    Categories: Therapeutic Use; Blood; Complications; Diagnosis; Drug Therapy; Metabolism
    Intravenous immunoglobulin as salvage therapy for refractory thrombotic thrombocytopenic purpura. (2018)
    Rituximab treatment for thrombotic thrombocytopenic purpura associated with human immunodeficiency virus failing extensive treatment with plasma exchange: a report of two cases. (2010)

  19. Poncz, Mortimer   Pediatric Hematology-Oncology  Google Publications
    Division of Hematology, Childrens Hospital of Philadelphia, PA K.G., D.F.F., M.P..
    Physician 
    Disclosed payments in 2021 from 2 biomedical companies, totalling $3,436, including $1,936 from  SANOFI-AVENTIS U.S. LLC
    Subjects: Purpura, Thrombotic Thrombocytopenic; Thrombosis; ADAM Proteins; ADAMTS13 Protein; Genetic Therapy
    Categories: Antagonists & Inhibitors; Complications; Immunology; Metabolism; Methods; Prevention & Control
    Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. (2015)
    ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model. (2016)

  20. Park, Yara A   Anatomic Pathology & Clinical Pathology   Google Publications
    Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA.
    Physician  Highly Published  Case Reports 
    Subjects: Purpura, Thrombotic Thrombocytopenic; Plasma Exchange; ADAM Proteins; ADAMTS13 Protein; Antineoplastic Agents; Autoantibodies
    Categories: Therapy; Blood; Diagnosis; Methods; Therapeutic Use; Immunology
    Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. (2014)
    Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults. (2010)

Note:
  1. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);